Literature DB >> 1700746

Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.

E Roussel1, J M Gerrard, A H Greenberg.   

Abstract

It has been reported that lymphocytes from peripheral blood (PBL) cultured with interleukin-2 (IL-2) produce predominantly CD16+ lymphokine-activated killer (LAK) cells. We developed a two-step method to generate LAK cells from human PBL in long-term cultures (10-12 days) with recombinant human IL-2 (rhIL-2) and characterized the evolving LAK cell population by testing its phenotype and cytotoxic activity as a function of time. The starting PBL displayed some natural killer (NK) cytotoxicity but no LAK activity. At day 6, the cells were a mixed population of about 80% CD3+ and 6% CD16+ cells. Little proliferation was evident but strong LAK activity was detected. After 10-12 days, major cell expansion had occurred and they were essentially a pure (greater than 90%) CD3+ CD16- CD56- cell population large granular lymphocyte (LGL) by morphology that displayed strong non-MHC-restricted killing activity (greater than 200 lytic units). Over the same period of time, the CD16+ cells had almost completely regressed in these cultures. This preferential induction of CD+ LAK cells was not an effect of IL-2 concentration as 10 U/ml was as effective as 500 U/ml. Further characterization revealed a major population of CD4+ (60%) and CD8+ (30%) with a smaller fraction (less than 9%) of gamma delta + cells. These results indicate that a virtually pure CD3+ LAK cells population was produced with long-term cultures of lymphocytes from peripheral blood in rhIL-2, in which active proliferation of the CD3+ but not CD16+ cells occurred.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700746      PMCID: PMC1535142          DOI: 10.1111/j.1365-2249.1990.tb05463.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.

Authors:  B Perussia; C Ramoni; I Anegon; M C Cuturi; J Faust; G Trinchieri
Journal:  Nat Immun Cell Growth Regul       Date:  1987

2.  CD3-negative lymphokine-activated cytotoxic cells express the CD3 epsilon gene.

Authors:  R Biassoni; S Ferrini; I Prigione; A Moretta; E O Long
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

3.  Phenotypic and functional heterogeneity of human cloned natural killer cell lines.

Authors:  T Hercend; E L Reinherz; S Meuer; S F Schlossman; J Ritz
Journal:  Nature       Date:  1983-01-13       Impact factor: 49.962

4.  Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.

Authors:  G Weil-Hillman; P Fisch; A F Prieve; J A Sosman; J A Hank; P M Sondel
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

5.  Self-protection of cytotoxic lymphocytes: a soluble form of homologous restriction factor in cytoplasmic granules.

Authors:  L S Zalman; M A Brothers; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

6.  Overnight incubation of mouse spleen cells in recombinant IL-2 generates cytotoxic cells with NK characteristics from precursors enriched with or devoid of LGL.

Authors:  A Punturieri; F Velotti; M Piccoli; R B Herberman; L Frati; A Santoni
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

7.  CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex.

Authors:  P Anderson; M Caligiuri; J Ritz; S F Schlossman
Journal:  Nature       Date:  1989-09-14       Impact factor: 49.962

8.  Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.

Authors:  A C Ochoa; D E Hasz; R Rezonzew; P M Anderson; F H Bach
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

9.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

10.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

View more
  3 in total

1.  Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.

Authors:  A Schomburg; H Kirchner; J Atzpodien
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans.

Authors:  S M Levitz
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

3.  Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.

Authors:  I Vollenweider; R Moser; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.